Sponsors Want Answers On Consequences Of Missing US FDA Trial Diversity Goals
No negative actions have been taken in the US FDA’s oncology review divisions, but vague diversity guidance continues to raise concerns.
You may also be interested in...
Rick Pazdur's wish for the National Cancer Institute to help industry speed US trial enrollment and diversity could get a boost if Congress fulfills Biden’s new fiscal year Cancer Moonshot funding request.
The director of the US FDA’s Center for Drug Evaluation and Research acknowledged that the FDA cannot improve trial diversity alone.
FDA Commissioner Robert Califf says mentioning China helps increase congressional support.